1. Home
  2. NGNE vs NX Comparison

NGNE vs NX Comparison

Compare NGNE & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$23.57

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo Quanex Building Products Corporation

NX

Quanex Building Products Corporation

SELL

Current Price

$18.68

Market Cap

834.5M

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
NGNE
NX
Founded
2003
1927
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
834.5M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
NGNE
NX
Price
$23.57
$18.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
2
Target Price
★ $77.88
$26.00
AVG Volume (30 Days)
354.4K
★ 379.4K
Earning Date
11-12-2026
09-03-2026
Dividend Yield
N/A
★ 1.66%
EPS Growth
★ 0.93
N/A
EPS
N/A
★ 0.57
Revenue
N/A
★ $1,837,641,000.00
Revenue This Year
N/A
$1.98
Revenue Next Year
N/A
$0.51
P/E Ratio
★ N/A
$33.89
Revenue Growth
N/A
★ 43.81
52 Week Low
$15.93
$11.04
52 Week High
$43.66
$23.33

Technical Indicators

Market Signals
Indicator
NGNE
NX
Relative Strength Index (RSI) 33.88 45.11
Support Level $16.88 $18.30
Resistance Level $29.16 $19.62
Average True Range (ATR) 1.99 0.76
MACD -0.13 0.01
Stochastic Oscillator 29.31 40.70

Price Performance

Historical Comparison
NGNE
NX

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: